Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia Areata significantly reduces quality of life, especially in women, long-term sufferers, and severe cases.

People with alopecia areata had lower vitamin D levels, but these levels didn't relate to many aspects of the condition.

DNCB is highly effective for treating alopecia areata with minimal long-term side effects.

Alopecia areata causes patchy hair loss due to unknown factors, affecting all ages and genders.

Diagnosing alopecia areata is challenging and requires careful examination and various tests to distinguish it from other hair loss types.

IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.

Vitamin D may help with certain types of hair loss in women.

Alopecia areata patients may have higher blood pressure and blood sugar, indicating a future risk of metabolic issues.

Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.

Oxidative stress may play a role in alopecia areata, but depression and suicide risk are similar to healthy peers.

BMD-1141 effectively regrows hair in alopecia areata with less frequent dosing than current treatments.

Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.

Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.

Tofacitinib effectively regrows hair in alopecia universalis triggered by a virus.

Patients with Alopecia Areata are willing to trade life duration for better quality of life.

Switching JAK inhibitors can lead to significant hair regrowth in severe alopecia cases.

A woman experienced total hair loss after an HPV vaccine, but treatment helped regrow her hair.

The Polish version of the Alopecia Areata Quality of Life Index is a reliable tool for assessing quality of life in Polish-speaking patients with alopecia areata.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Higher levels of certain DNAs in blood may indicate hair follicle damage in alopecia areata patients.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

Four genes are potential markers for hair loss condition alopecia areata, linked to a specific type of cell death.

Male gender and family history predict alopecia areata recurrence.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

These specific gene polymorphisms are not linked to Alopecia Areata in Egyptians.

Alopecia areata patients have higher levels of certain immune receptors, suggesting new treatment possibilities.

Oxidative stress is linked to mild patchy alopecia areata.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.